Founded in 2007, Regeneus are a Sydney-based regenerative medicine company developing a portfolio of innovative cell-based therapies, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms.The company has two product candidates in Phase 1 trials for humans, Progenza and RGSH4K. Regeneus is headquartered in New South Wales, Australia.